Abstract | INTRODUCTION: METHODS: We retrospectively analyzed the available bone marrow (BM) samples from 115 patients with myeloid neoplasms obtained before and during treatment with 5-azacytidine. A threshold of 100 copies in BM was used to define risk groups: group 1: patients with WT1 levels always below < 100 copies; group 2: cases with initial WT1 levels greater than 100 copies but with a conversion to sustained levels below 100; and group 3: cases with follow-up WT1 levels greater than 100. RESULTS: Twenty patients were included in group 1, 17 in group 2, and 78 in group 3. Survival analysis showed statistically significant differences in terms of OS between groups (p: 0.016). Patients in group 2 showed the best 5-year overall survival (OS). In multivariate analysis, only the cytogenetic risk category and receiving an allogeneic hematopoietic stem cell transplantation (HCT) independently predicted the survival. CONCLUSIONS: Further studies are needed to assess whether BM WT1 levels could be useful to predict the survival of patients with myeloid neoplasms treated with 5-azacytidine.
|
Authors | Marta Santaliestra, Ana Garrido, Maite Carricondo, Elena Bussaglia, Marta Pratcorona, Maria L Blanco, Ignasi Gich, Montserrat Hoyos, Albert Esquirol, Irene García-Cadenas, Salut Brunet, Rodrigo Martino, Jorge Sierra, Josep F Nomdedéu |
Journal | European journal of haematology
(Eur J Haematol)
Vol. 103
Issue 3
Pg. 208-214
(Sep 2019)
ISSN: 1600-0609 [Electronic] England |
PMID | 31211880
(Publication Type: Journal Article)
|
Copyright | © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antimetabolites, Antineoplastic
- WT1 Proteins
- WT1 protein, human
- Azacitidine
|
Topics |
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic
(pharmacology, therapeutic use)
- Azacitidine
(pharmacology, therapeutic use)
- Bone Marrow Cells
(metabolism)
- Combined Modality Therapy
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
(drug therapy, genetics)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(drug therapy, genetics)
- Myeloproliferative Disorders
(drug therapy, genetics, metabolism, pathology)
- Transplantation, Homologous
- Treatment Outcome
- WT1 Proteins
(genetics, metabolism)
|